Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine

Scaramuzzi, Karina; Oliveira, Denise Cristina André; Carvalho, L.; Tambourgi, Denise V.; Tenório, Elisabeth Christina Nunes; Rizzi, Marisa; Mussalem, Juliana Sekeres; Fantini, Márcia Carvalho de Abreu; Botosso, Viviane Fongaro; ́Anna, Osvaldo Augusto Sant

doi:10.1590/s1679-45082011ao2162

Cited by 14 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously described, silica SBA-15 presents physicochemical properties that may protect different compounds from possible degradation by digestive acids and enzymes. This property allows for the oral administration of some antigens, such as hepatitis B vaccine, which before the conjugation had no effect [46]. It is known that CTX when orally administrated has no effect, since as a protein, it has low oral bioavailability [47].…”

Section: Discussionmentioning

confidence: 99%

Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice

Sant’Anna

Lopes

Kimura

et al. 2019

Toxins

View full text Add to dashboard Cite

Neuropathic pain is a disease caused by structural and functional plasticity in central and peripheral sensory pathways that produce alterations in nociceptive processing. Currently, pharmacological treatment for this condition remains a challenge. Crotoxin (CTX), the main neurotoxin of Crotalus durissus terrificus rattlesnake venom, has well described prolonged anti-inflammatory and antinociceptive activities. In spite of its potential benefits, the toxicity of CTX remains a limiting factor for its use. SBA-15 is an inert nanostructured mesoporous silica that, when used as a vehicle, may reduce toxicity and potentiate the activity of different compounds. Based on this, we propose to conjugate crotoxin with SBA-15 (CTX:SBA-15) in order to investigate if when adsorbed to silica, CTX would have its toxicity reduced and its analgesic effect enhanced in neuropathic pain induced by the partial sciatic nerve ligation (PSNL) model. SBA-15 enabled an increase of 35% of CTX dosage. Treatment with CTX:SBA-15 induced a long-lasting reduction of mechanical hypernociception, without modifying the previously known pathways involved in antinociception. Moreover, CTX:SBA-15 reduced IL-6 and increased IL-10 levels in the spinal cord. Surprisingly, the antinociceptive effect of CTX:SBA-15 was also observed after oral administration. These data indicate the potential use of the CTX:SBA-15 complex for neuropathic pain control and corroborates the protective potential of SBA-15.

show abstract

Section: Discussionmentioning

confidence: 99%

Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice

Sant’Anna

Lopes

Kimura

et al. 2019

Toxins

View full text Add to dashboard Cite

show abstract

“…Together, these properties allow the safe transport of small molecules through the TGI. [51][52][53][54][55][56] In fact, by modeling the SAXS data, in combination with the NAI results, it was possible to conclude that a fraction of the Ac2-26 peptide was loaded into the SBA-15 mesopores. In contrast, the remaining amount is on the silica surface, a similar scenario observed in previous studies, 44,57 in which the authors loaded proteins instead of peptides.…”

Section: Discussionmentioning

confidence: 99%

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases

Broering,

Oseliero Filho,

Borges

et al. 2024

IJN

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) disrupt the intestinal epithelium, leading to severe chronic inflammation. Current therapies cause adverse effects and are expensive, invasive, and ineffective for most patients. Annexin A1 (AnxA1) is a pivotal endogenous anti-inflammatory and tissue repair protein in IBD. Nanostructured compounds loading AnxA1 or its active N-terminal mimetic peptides improve IBD symptomatology. Methods: To further explore their potential as a therapeutic candidate, the AnxA1 N-terminal mimetic peptide Ac2-26 was incorporated into SBA-15 ordered mesoporous silica and covered with EL30D-55 to deliver it by oral treatment into the inflamed gut. Results:The systems SBA-Ac2-26 developed measurements revealed self-assembled rod-shaped particles, likely on the external surface of SBA-15, and 88% of peptide incorporation. SBA-15 carried the peptide Ac2-26 into cultured Raw 264.7 macrophages and Caco-2 epithelial cells. Moreover, oral administration of Eudragit-SBA-15-Ac2-26 (200 μg; once a day; for 4 days) reduced colitis clinical symptoms, inflammation, and improved epithelium recovery in mice under dextran-sodium sulfate-induced colitis. Discussion: The absorption of SBA-15 in gut epithelial cells is typically low; however, the permeable inflamed barrier can enable microparticles to cross, being phagocyted by macrophages. These findings suggest that Ac2-26 is successfully delivered and binds to its receptors in both epithelial and immune cells, aligning with the clinical results. Conclusion: Our findings demonstrate a simple and cost-effective approach to delivering Ac2-26 orally into the inflamed gut, highlighting its potential as non-invasive IBD therapy.

show abstract

“…About seven days before the oral vaccination administration, the dry fraction of the vaccine was prepared, measuring the number of proteins suspended in PBS (pH 7.2). The dose used for the production of the oral vaccine was 200 µg per piglet, mixed with silica in the proportion 1:35 defined in previous studies [ 14 , 26 ]. Mycoplasma hyopneumoniae protein lysate was added to SBA-15, previously macerated and activated, and a drying step at 37 °C for 72 h was performed to obtain the dry fraction [ 16 ].…”

Section: Methodsmentioning

confidence: 99%

“…The chemical, mechanical, and thermal stability of silica, along with its high surface area and mesopores in the range of 8–50 nm with a narrow distribution, allows for the incorporation and release of molecules. This sets it apart from other adjuvants, such as aluminum hydroxide [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control Mycoplasma hyopneumoniae in Swine Production

Storino

Petri

Mechler-Dreibi

et al. 2023

IJMS

View full text Add to dashboard Cite

Mycoplasma hyopneumoniae is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from Mycoplasma hyopneumoniae and incorporated into mesoporous silica (SBA-15), which has an adjuvant-carrier function, aiming to potentiate the action of the commercial intramuscular vaccine. A total of 60 piglets were divided into four groups (n = 15) submitted to different vaccination protocols as follows, Group 1: oral SBA15 + commercial vaccine at 24 days after weaning, G2: oral vaccine on the third day of life + vaccine commercial vaccine at 24 days, G3: commercial vaccine at 24 days, and G4: commercial vaccine + oral vaccine at 24 days. On the first day, the piglets were weighed and, from the third day onwards, submitted to blood collections for the detection and quantification of anti-Mycoplasma hyopneumoniae IgG. Nasal swabs were collected to monitor IgA by ELISA, and oropharyngeal swabs were used to assess the bacterial load by qPCR. Biological samples were collected periodically from the third day of life until the 73rd day. At 41 days of life, 15 individuals of the same age, experimentally challenged with an inoculum containing M. hyopneumoniae, were co-housed with the animals from groups (1 to 4) in a single pen to increase the infection pressure during the nursery period. At 73 days, all piglets were euthanized, and lungs were evaluated by collecting samples for estimation of bacterial load by qPCR. Quantitative data obtained from physical parameters and laboratory investigation were analyzed by performing parametric or non-parametric statistical tests. Results indicate that animals from G2 showed smaller affected lung areas compared to G3. Animals from G2 and G4 had a low prevalence of animals shedding M. hyopneumoniae at 61 days of age. Additionally, no correlation was observed between lung lesions and M. hyopneumoniae load in lung and BALF samples in animals that received the oral vaccine, while a strong correlation was observed in other groups. In the present study, evidence points to the effectiveness of the oral vaccine developed for controlling M. hyopneumoniae in pig production under field conditions.

show abstract

Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine

Abstract: Our results clearly indicate the promising use of SBA-15 as an adjuvant, especially in oral immunizations.

Cited by 14 publications

References 25 publications

Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice

Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases

Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control Mycoplasma hyopneumoniae in Swine Production

Contact Info

Product

Resources

About